Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 5/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687662 | 0.88 | MAP2K1 (0.63) | MAP2K1KDR | |
| SCHEMBL5138174 | 0.78 | MAP2K1 (0.55) | MAP2K1GAA | |
| SCHEMBL3695752 | 0.76 | MAP2K1 (0.61) | MAP2K1 | |
| SCHEMBL3684141 | 0.75 | MAP2K1 (0.60) | MAP2K1GAA | |
| SCHEMBL3695515 | 0.75 | MAP2K1 (0.52) | MAP2K1GAA | |
| SCHEMBL6054317 | 0.74 | MAP2K1 (0.55) | MAP2K1KDR | |
| SCHEMBL6054394 | 0.72 | MAP2K1 (0.66) | MAP2K1 | |
| SCHEMBL5148015 | 0.72 | MAP2K1 (0.49) | MAP2K1 | |
| SCHEMBL1228138 | 0.72 | KDR (0.55) | MAP2K1KDRMAPK14 | |
| SCHEMBL5184617 | 0.71 | MAP2K1 (0.87) | MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664051-A4 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-1664051-A2 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Bristol-Myers Squibb Company (US) | 2006-06-07 | — | — | EP | disclosed |
| US-7030112-B2 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-18 | — | — | US | disclosed |
| WO-2005030144-A2 | PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20040209886-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209886-A1 | Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders | PCNA, DPYD, MALT1 | MAP2K1 882/4885GAA 1087/4885KDR 2857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.